FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216898889> ?p ?o ?g. }

• W3216898889 endingPage "5098" @default.
• W3216898889 startingPage "5089" @default.
• W3216898889 abstract "Linezolid (LNZ), an oxazolidinone antibiotic, has 100% oral bioavailability and favorable activities against gram-positive pathogens. The in vitro PK/PD model was developed based on concentrations obtained with routine doses in humans can be used to guide dose optimization in the clinic.In this study, we employed an in vitro PK/PD model to simulate the changes in the plasma concentration of linezolid in the human body against a clinical isolate of MRSA in vitro. A high-performance liquid chromatography (HPLC)-UV method was applied to measure the concentration of linezolid. Bacterial samples were collected at different times from the central compartment for count.The chromatographic separation was carried out with an AichromBond-AQC18 column(250mm×4.6mm, 5μm), using a mobile phase of water with 0.1% formic acid:acetonitrile 70:30 (v/v), followed by detection at 254 nm, and a single detection run was completed within 10 min. The method was validated by estimating the precision and accuracy for the inter- and intra-day analyses in the concentration range of 0.25-32 mg/L. The method was linear over the investigated range of 0.125-32 mg/L, with all correlation coefficients R2 = 0.9999. The intra-day and inter-day precisions were within 7.598%, and the method recovery ranged from 90.912% to 106.459%. In vitro PK/PD model, both the absorption and elimination of linezolid being simulated can be precisely controlled by computer. In the control group, the bacterial reached 7.9 Log10CFU/mL in the first 48h and maintained until the end, indicating that the colonies grew well in vitro PK/PD model. In the linezolid 600 mg q12h administration group, the colony decreased to 2.39 Log10CFU/mL at 24h, showing a good bactericidal effect; however, the colonies resumed growth to the initial level in 48h, indicating an emergence of resistance.We successfully established an in vitro infection PK/PD model and developed an HPLC-UV method to determine linezolid concentration for resistance investigation. The results suggest that the 600 mg q12h dosing regimen may no longer be applicable and requires optimization." @default.
• W3216898889 created "2021-12-06" @default.
• W3216898889 creator A5001127933 @default.
• W3216898889 creator A5005498738 @default.
• W3216898889 creator A5012635924 @default.
• W3216898889 creator A5021004725 @default.
• W3216898889 creator A5021404192 @default.
• W3216898889 creator A5031689618 @default.
• W3216898889 creator A5042467158 @default.
• W3216898889 creator A5069950304 @default.
• W3216898889 creator A5079766796 @default.
• W3216898889 date "2021-12-01" @default.
• W3216898889 modified "2023-09-27" @default.
• W3216898889 title "Development and Validation of an HPLC-UV Method for Quantitation of Linezolid: Application to Resistance Study Using in vitro PK/PD Model" @default.
• W3216898889 cites W2006139700 @default.
• W3216898889 cites W2040162230 @default.
• W3216898889 cites W2049304410 @default.
• W3216898889 cites W2053558923 @default.
• W3216898889 cites W2054145184 @default.
• W3216898889 cites W2057692381 @default.
• W3216898889 cites W2076952840 @default.
• W3216898889 cites W2077608176 @default.
• W3216898889 cites W2081422800 @default.
• W3216898889 cites W2088261635 @default.
• W3216898889 cites W2098835103 @default.
• W3216898889 cites W2100833332 @default.
• W3216898889 cites W2108072142 @default.
• W3216898889 cites W2109943119 @default.
• W3216898889 cites W2110883821 @default.
• W3216898889 cites W2116888562 @default.
• W3216898889 cites W2121257383 @default.
• W3216898889 cites W2121637951 @default.
• W3216898889 cites W2132754760 @default.
• W3216898889 cites W2138950142 @default.
• W3216898889 cites W2140643555 @default.
• W3216898889 cites W2144143337 @default.
• W3216898889 cites W2144624679 @default.
• W3216898889 cites W2152320283 @default.
• W3216898889 cites W2153039659 @default.
• W3216898889 cites W2303864335 @default.
• W3216898889 cites W2740270712 @default.
• W3216898889 cites W2741180806 @default.
• W3216898889 cites W2792688383 @default.
• W3216898889 cites W2799718177 @default.
• W3216898889 cites W2898812637 @default.
• W3216898889 cites W2942109186 @default.
• W3216898889 cites W2979388008 @default.
• W3216898889 cites W3126772246 @default.
• W3216898889 doi "https://doi.org/10.2147/idr.s343200" @default.
• W3216898889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34880634" @default.
• W3216898889 hasPublicationYear "2021" @default.
• W3216898889 type Work @default.
• W3216898889 sameAs 3216898889 @default.
• W3216898889 citedByCount "1" @default.
• W3216898889 countsByYear W32168988892023 @default.
• W3216898889 crossrefType "journal-article" @default.
• W3216898889 hasAuthorship W3216898889A5001127933 @default.
• W3216898889 hasAuthorship W3216898889A5005498738 @default.
• W3216898889 hasAuthorship W3216898889A5012635924 @default.
• W3216898889 hasAuthorship W3216898889A5021004725 @default.
• W3216898889 hasAuthorship W3216898889A5021404192 @default.
• W3216898889 hasAuthorship W3216898889A5031689618 @default.
• W3216898889 hasAuthorship W3216898889A5042467158 @default.
• W3216898889 hasAuthorship W3216898889A5069950304 @default.
• W3216898889 hasAuthorship W3216898889A5079766796 @default.
• W3216898889 hasBestOaLocation W32168988891 @default.
• W3216898889 hasConcept C112705442 @default.
• W3216898889 hasConcept C125287762 @default.
• W3216898889 hasConcept C159985019 @default.
• W3216898889 hasConcept C179998833 @default.
• W3216898889 hasConcept C181389837 @default.
• W3216898889 hasConcept C185592680 @default.
• W3216898889 hasConcept C192562407 @default.
• W3216898889 hasConcept C202751555 @default.
• W3216898889 hasConcept C2777379063 @default.
• W3216898889 hasConcept C2778980435 @default.
• W3216898889 hasConcept C2779489039 @default.
• W3216898889 hasConcept C2781414143 @default.
• W3216898889 hasConcept C43617362 @default.
• W3216898889 hasConcept C523546767 @default.
• W3216898889 hasConcept C54355233 @default.
• W3216898889 hasConcept C55493867 @default.
• W3216898889 hasConcept C71924100 @default.
• W3216898889 hasConcept C86803240 @default.
• W3216898889 hasConcept C98274493 @default.
• W3216898889 hasConceptScore W3216898889C112705442 @default.
• W3216898889 hasConceptScore W3216898889C125287762 @default.
• W3216898889 hasConceptScore W3216898889C159985019 @default.
• W3216898889 hasConceptScore W3216898889C179998833 @default.
• W3216898889 hasConceptScore W3216898889C181389837 @default.
• W3216898889 hasConceptScore W3216898889C185592680 @default.
• W3216898889 hasConceptScore W3216898889C192562407 @default.
• W3216898889 hasConceptScore W3216898889C202751555 @default.
• W3216898889 hasConceptScore W3216898889C2777379063 @default.
• W3216898889 hasConceptScore W3216898889C2778980435 @default.
• W3216898889 hasConceptScore W3216898889C2779489039 @default.
• W3216898889 hasConceptScore W3216898889C2781414143 @default.
• W3216898889 hasConceptScore W3216898889C43617362 @default.

• next